ALXO Overview

Positive Trial Results: ALX Oncology's shares rose over 7% following promising results from a phase 2 trial of Evorpacept for treating indolent B-cell non-Hodgkin lymphoma, presented at the American Society of Haematology Annual Meeting 2025.

Efficacy of Evorpacept: The trial showed a 92% complete response rate in patients treated with Evorpacept in combination with rituximab and lenalidomide, significantly higher than the historical 50% response rate for the standard treatment alone.

Survival Rates: The combination therapy demonstrated a one-year progression-free survival rate of 91% and a one-year overall survival rate of 100%, indicating strong anti-tumor activity and tolerability.

Market Reaction: Following the announcement, ALX Oncology's stock closed at $1.42, reflecting a 3.65% increase from the previous trading day.

Precision Oncology Market Growth: The precision oncology sector is rapidly evolving, with the market reaching $106.21 billion in 2025 and projected to grow to $158.9 billion by 2029, driven by advancements in biomarker-driven therapies and immunotherapy modalities.

Oncolytics Biotech's Pivotal Trial: Oncolytics Biotech has received FDA alignment for its Phase 3 study of pelareorep in pancreatic cancer, aiming to provide the first immunotherapy option for this indication, with promising preliminary data showing significant response rates.

ALX Oncology's Clinical Success: ALX Oncology reported a 65% objective response rate for its candidate evorpacept in treating high CD47-expressing HER2-positive gastric cancer, significantly outperforming standard therapies and guiding future clinical strategies.

Innovations from Other Biotech Firms: Companies like Erasca, Immuneering, and Prelude Therapeutics are advancing their respective therapies and programs, with notable achievements in patent protections and promising clinical trial results, indicating a strong pipeline in the oncology sector.